C4 Therapeutics (CCCC) AI Stock Analysis

• Market Cap: $224.90M
• Dividend Yield: N/A
• Average Volume (3M): 1.43M
• Price to Earnings (P/E): ―
• Beta (1Y): 3.47
• Revenue Growth: 16.55%
• EPS Growth: 16.73%
• Country: US
• Employees: 110
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.37
• Shares Outstanding: 71,170,815
• 10 Day Avg. Volume: 1,728,099
• 30 Day Avg. Volume: 1,429,969
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: -0.22
• Enterprise Value/Revenue: -1.46
• Enterprise Value/Gross Profit: -1.65
• Enterprise Value/Ebitda: 0.45
• 1Y Price Target: $7.75
• Price Target Upside: 145.25% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

• Rating: 58 Neutral
• Price Target: $3.50 ▲(10.76% Upside)

C4 Therapeutics' overall stock score is primarily influenced by its strong technical performance, indicating bullish momentum. However, significant financial challenges and a poor valuation due to ongoing losses weigh heavily on the score. The lack of earnings call data and corporate events means these factors do not influence the score.

Positive Factors

Strategic Partnerships

The acceptance of Biogen's IND application highlights the strength of C4 Therapeutics' strategic partnerships, which are crucial for advancing drug candidates and leveraging its TORPEDO platform. This collaboration enhances C4's capabilities and potential market reach.

Pipeline Progress

The completion of Phase 1 trial enrollment and positive safety and efficacy data for cemsidomide indicate promising pipeline progress. This advancement supports long-term growth prospects and potential market entry for new treatments.

Revenue Growth

Consistent revenue growth, despite operational challenges, demonstrates the company's ability to expand its market presence and leverage its technology platform for future growth opportunities.

Negative Factors

Profitability Challenges

Ongoing profitability challenges, with negative EBIT and net income, indicate operational inefficiencies. This could hinder long-term financial health and necessitates strategic adjustments to improve cost management and revenue generation.

Cash Flow Issues

Negative cash flows highlight inefficiencies in cash generation and management, posing risks to financial stability. Addressing these issues is crucial for sustaining operations and funding future growth initiatives.

Financial Stability

Persistent financial challenges, including ongoing losses, threaten the company's financial stability. Without improvements in operational efficiency and revenue generation, long-term sustainability could be compromised.

C4 Therapeutics Business Overview & Revenue Model

Company Description

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

How the Company Makes Money

C4 Therapeutics generates revenue primarily through strategic collaborations and partnerships with other biotechnology and pharmaceutical companies. These agreements typically involve upfront payments, milestone payments, and potential royalties based on the successful development and commercialization of TPD therapies. The company's partnerships often focus on leveraging its TORPEDO platform to advance novel drug candidates through various stages of clinical development. While C4 Therapeutics is actively engaged in research and development activities, its revenue model is heavily reliant on these collaborations to fund its operations and growth initiatives.

C4 Therapeutics Financial Statement Overview

Summary

C4 Therapeutics faces significant financial challenges, with persistent losses impacting profitability and cash flows. While the balance sheet remains relatively stable, the company needs to address its operational inefficiencies to improve financial health. Strategic adjustments may be necessary to enhance revenue generation and cost management to achieve sustainable growth.

Income Statement

The income statement reveals a company struggling with profitability. The TTM (Trailing-Twelve-Months) shows negative EBIT and net income, indicating operational challenges. Although there's a modest revenue growth of 11.8% from the previous year, margins remain negative, suggesting ongoing difficulties in cost management or revenue generation.

Balance Sheet

The balance sheet shows a reasonable equity ratio of 61.07%, indicating a solid capital structure with more assets funded by equity. However, the debt-to-equity ratio of 0.33 reflects manageable leverage but could pose risks if financial performance does not improve. Return on equity remains negative due to ongoing losses.

Cash Flow

Cash flow analysis indicates issues with cash generation, as both operating and free cash flows are negative in the TTM (Trailing-Twelve-Months). The operating cash flow to net income ratio is negative, pointing to inefficiencies in converting sales into cash, while free cash flow is deteriorating, signaling cash management challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	34.24M	35.58M	20.76M	31.10M	45.78M	33.20M
Gross Profit	30.42M	35.58M	13.02M	23.52M	42.88M	-45.24M
EBITDA	-112.50M	-103.37M	-122.10M	-124.28M	-78.84M	-62.89M
Net Income	-111.58M	-105.32M	-132.49M	-128.18M	-83.89M	-66.33M
Balance Sheet
Total Assets	296.53M	349.60M	376.45M	430.84M	506.76M	400.14M
Cash, Cash Equivalents and Short-Term Investments	214.55M	244.90M	253.68M	276.15M	309.28M	371.69M
Total Debt	62.92M	65.76M	70.98M	87.15M	42.88M	22.92M
Total Liabilities	122.46M	133.62M	130.34M	141.61M	117.16M	119.35M
Stockholders Equity	174.06M	215.99M	246.11M	289.23M	389.61M	280.79M
Cash Flow
Free Cash Flow	-87.58M	-65.34M	-108.55M	-111.44M	-88.24M	-67.90M
Operating Cash Flow	-87.41M	-65.16M	-106.84M	-105.94M	-86.97M	-67.25M
Investing Cash Flow	81.88M	-51.27M	158.35M	58.42M	-189.34M	-190.50M
Financing Cash Flow	10.57M	45.34M	45.49M	1.15M	171.40M	348.93M

C4 Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.16
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CCCC, the sentiment is Positive. The current price of 3.16 is above the 20-day moving average (MA) of 2.81, above the 50-day MA of 2.51, and above the 200-day MA of 2.46, indicating a bullish trend. The MACD of 0.24 indicates Negative momentum. The RSI at 61.29 is Neutral, neither overbought nor oversold. The STOCH value of 66.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CCCC.

C4 Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CCCC	58 Neutral	$224.90M	―	-52.99%	―	16.55%	16.73%
ZNTL	46 Neutral	109.65M	-0.67	0.00%	―	-33.76%	17.10%
ZURA	43 Neutral	129.39M	-2.62	0.00%	―	0.00%	-50.20%
CLYM	41 Neutral	156.54M	-3.33	0.00%	―	0.00%	67.69%
KYTX	36 Underperform	250.82M	-1.58	0.00%	―	0.00%	-39.69%
VOR	33 Underperform	186.35M	-0.10	0.00%	―	0.00%	-686.12%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

C4 Therapeutics Corporate Events

C4 Therapeutics Completes Phase 1 Trial Enrollment

On August 7, 2025, C4 Therapeutics announced the completion of enrollment and dose escalation for its Phase 1 trial of cemsidomide in multiple myeloma (MM) and non-Hodgkin’s lymphoma (NHL), showing promising response rates. The company plans to align with the FDA on a Phase 2 dose by the end of 2025 and initiate registrational development in early 2026, focusing on MM treatment. Financially, C4T reported a decrease in revenue for Q2 2025 compared to the previous year, primarily due to a previous milestone payment, but maintained a strong cash position expected to fund operations until mid-2027.

The most recent analyst rating on (CCCC) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on C4 Therapeutics stock, see the CCCC Stock Forecast page.